Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Open Label Phase II Study of Daratumumab in Combination With Dexamethasone in Multiple Myeloma Resistant or Refractory to Bortezomib and Lenalidomide and Pomalidomide - an IFM 2014-04 Study

NCT02626481 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT02626481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02626481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Open Label Phase II Study of Daratumumab in Combination With Dexamethasone in Multiple Myeloma Resistant or Refractory to Bortezomib and Lenalidomide and Pomalidomide - an IFM 2014-04 Study
Lead sponsor
University Hospital, Lille
Phase
Phase 2
Overall status
Completed
Start date
December 28, 2015
Completion date
March 9, 2020
Enrollment
64 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma